diaDexus investigates uterine cancer serum test:
This article was originally published in Clinica
diaDexus is investigating the feasibility of a noninvasive serum test for uterine and endometrial cancers. The test identifies the gene hESFI (human endometrial specific steroid binding factor I), which is highly expressed in the cancers, or the gene's protein. The Santa Clara, California firm recently received a US patent covering the technology.